



AnaptysBio

*Leader in SHM for
Antibody Therapeutics*

FOR IMMEDIATE RELEASE

February 3, 2009

**AnaptysBio Names Vice President to Lead
Therapeutic Antibody Preclinical Development Efforts**

*Tabrizi to shepherd therapeutic monoclonal antibodies discovered using
proprietary Somatic Hypermutation (SHM) platform into the clinic*

SAN DIEGO, CA – AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced the appointment of Dr. Mohammad Tabrizi as vice president of preclinical development. Tabrizi brings extensive experience in the research and development of monoclonal antibodies to the San Diego-based company as it continues to implement its strategic growth plan for 2009 and beyond.

“Mohammad will manage preclinical development of our internal therapeutic antibody product candidates,” said Tom Smart, chairman and chief executive officer. “This is a key hire for AnaptysBio as we move to the next stages of advancing product candidates arising from our SHM platform.”

In his role as vice president of preclinical development, Tabrizi will guide the company’s therapeutic antibody discovery programs into clinical development. He will also lead compound assessment, pharmacology, toxicology, bioanalytics and clinical immunology efforts, and will provide strategic input for target selection and generation of new drug concepts.

Tabrizi joins AnaptysBio from MedImmune, a subsidiary of AstraZeneca. At MedImmune he served as director of translational sciences and designed and implemented strategies for the development of therapeutic monoclonal antibodies from discovery to the clinic. Additional areas of expertise include preclinical pharmacology and safety; preclinical and clinical pharmacokinetics; pharmacodynamics; GLP-compliant bioanalytics; and clinical pharmacology of therapeutic monoclonal antibodies.

Tabrizi’s leadership experience includes contributing to the establishment of the AstraZeneca R&D facilities in Hayward, California, where he played a vital role in the integration of the team into the global company.

He also has held various leadership and scientific positions at AstraZeneca; Abgenix, Inc. (now Amgen, Inc.); Coulter Pharmaceutical, Inc. (now Corixa); and TAP holdings, Inc. Tabrizi holds a bachelor’s of science in pharmacy from University of Houston and a Ph.D. from University at Buffalo, State University of New York (SUNY) in the area of pharmacokinetics and pharmaceutical sciences. He completed his postdoctoral training in pharmacology at SUNY with a focus on therapeutics.

About AnaptysBio

Founded in 2005, AnaptysBio, Inc is a privately-held therapeutic antibody product company and the leader in the use of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is

the body's natural process for generating potent antibodies to fight disease. The Company's SHM-Platform™ utilizes the key components of SHM and other techniques to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection – a process that has been referred to as “naturalizing” antibodies. This versatile platform can be used both to discover and optimize antibodies directed at specific disease targets and also affinity mature existing antibodies to improve their binding properties. The company has established broad intellectual property around the use of SHM for therapeutic antibody applications, and is currently building a pipeline of novel therapeutic antibody product candidates. For more information, visit www.anaptysbio.com.

Contacts:

Gable PR – 619-284-1714

Erin Koch
erin.koch@gablepr.com
Cell: 619-246-9249

Tom Gable
tom@gablepr.com
Cell: 619-251-3881